Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + metformin + YH14755
- Development stage
- Unknown
- Lead developer
- Yuhan
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A **fixed dose combination** product containing **rosuvastatin** (an HMG-CoA reductase inhibitor/statin), **metformin** (a biguanide antihyperglycemic agent), and YH14755. It has been developed by Yuhan Corporation primarily for the treatment of **type 2 diabetes mellitus with dyslipidemia**. Rosuvastatin reduces cholesterol by inhibiting HMG-CoA reductase, lowering LDL and total cholesterol; metformin lowers blood glucose via inhibition of hepatic gluconeogenesis and stimulation of AMP-activated protein kinase (AMPK). YH14755 is a proprietary, fixed-dose co-formulation developed as a single product for dual management of hyperlipidemia and hyperglycemia in patients with type 2 diabetes and dyslipidemia. Clinical trial evidence (e.g., NCT02586129) supports efficacy in both glycemic and lipid endpoints[2][4][6][8].
- Brand names
- Rosumet
- Other names
- rosuvastatin/metformin - Yuhanmetformin/rosuvastatinmetformin + rosuvastatin + YH14755
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on rosuvastatin + metformin + YH14755.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + metformin + YH14755.